Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 703 record(s)

Req # A-2020-000226

Adverse Reaction Reports (AERs) for NASONEX. Report numbers: E2B_00337420, E2B_00338336, 000653339, 000670364, E2B_00542181, 000672686, E2B_00676666, E2B_00421946, E2B_00818817, E2B_00317517, E2B_00803713, 000664071, 000673054, E2B_00797172, E2B_00572127, 000308092, E2B_00859292, E2B_00865616.

Organization: Health Canada

611 page(s)
March 2021

Req # A-2020-000241

Adverse Reaction Reports (AERs) for ZENHALE. Report numbers: 000546550, E2B_00037157, E2B_00282538, E2B_00356618, E2B_01322347, E2B_01490363, E2B_01907640.

Organization: Health Canada

2742 page(s)
March 2021

Req # A-2020-000250

Adverse Reaction Reports (AERs) for FUROSEMIDE. Report numbers: E2B_02714932, E2B_02698395, E2B_02669273, E2B_02760580, E2B_02736554, E2B_02673074, E2B_02769575, E2B_02643642, E2B_02721613, E2B_02758498, E2B_02115509, E2B_02745409, E2B_02703856.

Organization: Health Canada

401 page(s)
March 2021

Req # A-2020-000251

Adverse Reaction Reports (AERs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_02796933, E2B_02753830, E2B_02794433.

Organization: Health Canada

68 page(s)
March 2021

Req # A-2020-000326

Adverse Reaction Reports (AERs) for Mezavant. Report numbers: E2B_02825035, E2B_02882429, E2B_02907794, E2B_02913170, E2B_02913375, E2B_02973212, E2B_02959658, E2B_02955630, E2B_02955280, E2B_02944188, E2B_02933965, E2B_02931008, E2B_02925932.

Organization: Health Canada

146 page(s)
March 2021

Req # A-2020-000345

Adverse Reaction Reports (AERs) for DOCETAXEL. Report numbers: 730196, 730327, E2B_02732623, E2B_02753818, E2B_02762244, E2B_02762344, E2B_02800999, E2B_02802349, E2B_02803762, E2B_02803765, E2B_02803797.

Organization: Health Canada

110 page(s)
March 2021

Req # A-2020-000347

Adverse Drug Reaction (ADR) for BISACODYL. Report number: 730804.

Organization: Health Canada

7 page(s)
March 2021

Req # A-2020-000364

Adverse Drug Reaction (ADR) for TERIFLUNOMIDE. Report number: E2B_02791526.

Organization: Health Canada

12 page(s)
March 2021

Req # A-2020-000406

Adverse Reaction Reports (AERs). Report numbers: 000911061, 000912202, 000912665, E2B_02987894.

Organization: Health Canada

48 page(s)
March 2021

Req # A-2020-000527

Adverse Reaction Reports (AERs) for FLUDARABINE PHOSPHATE. Report numbers: E2B_02951555, E2B_02951583, E2B_02955577, E2B_02955586, E2B_02955589, E2B_02955606, E2B_02955634, E2B_02955779, E2B_02955808, E2B_02955816, E2B_00056421, E2B_02959450.

Organization: Health Canada

118 page(s)
March 2021
Date modified: